CRISPR-Cas systems, defense systems in bacteria, have become a plentiful source of technologies for molecular diagnostics.
MacroGenics investigates three patient deaths in Phase 2 prostate cancer drug trial
MacroGenics reported on Thursday afternoon that three patients died in a mid-stage trial of its antibody-drug conjugate for prostate cancer. Two participants died due to